AN2 Therapeutics (ANTX) Operating Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Operating Expenses data on file, last reported at $10.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $10.6 million, down 8.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.1 million (down 25.8% YoY), and the FY2025 annual result was $38.1 million, down 32.89% from the prior year.
• Operating Expenses advanced to $10.6 million in Q1 2026 per ANTX's latest filing, from $9.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $18.8 million in Q4 2023 and troughed at $7.2 million in Q2 2025.
• A 5-year average of $12.8 million and a median of $11.8 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 274.78% in 2022, then sank 54.56% in 2025.
• A 5-year view of Operating Expenses shows it stood at $12.5 million in 2022, then jumped by 50.81% to $18.8 million in 2023, then sank by 54.3% to $8.6 million in 2024, then climbed by 8.35% to $9.3 million in 2025, then rose by 13.26% to $10.6 million in 2026.
• Business Quant data shows ANTX's Operating Expenses at $10.6 million in Q1 2026, $9.3 million in Q4 2025, and $10.0 million in Q3 2025.